A patient has died after having the Oxford/AstraZeneca vaccine and Denmark has now suspend the rollout whilst they investigate.
It is not known yet if there is any connection to patient having the Oxford/AstraZeneca jab and dying of the blood clot.
The Danish Health Minister has said they are “acting early” whilst they investigate the report of the death to see if there is any connection.
Denmark’s Health Minister, Magnus Heunicke wrote on Twitter, “The health authorities have, due to precautionary measures, suspended vaccination with AstraZeneca following a signal of a possible serious side effect in the form of fatal blood clots.
“It is currently not possible to conclude whether there is a connection. We act early, it needs to be thoroughly investigated.”
Austria has also suspended the use of the Oxford vaccine as they also had one batch which had related to blood clots and one death.
Despite this UK and international authorities have found the vaccine to be safe and effective in all adults and is in widespread use across the world.
The EMA, the EU’s drugs watchdog, said, “There is currently no indication that vaccination has caused these conditions, which are not listed as side effects with this vaccine.”
EMA are also investigating the possibility of a defect in a batch of 1m doses shipped to 17 EU countries.
The regulator said, “Although a quality defect is considered unlikely at this stage, the batch quality is being investigated.”
In a statement, the EMA added, “The information available so far indicates that the number of thromboembolic events in vaccinated people is no higher than that seen in the general population.
“As of March 9, 2021, 22 cases of thromboembolic events had been reported among the 3 million people vaccinated with COVID-19 Vaccine AstraZeneca in the European Economic Area.”
An AstraZeneca spokesperson said, “Patient safety is the highest priority for AstraZeneca. Regulators have clear and stringent efficacy and safety standards for the approval of any new medicine, and that includes COVID-19 Vaccine AstraZeneca.
“The safety of the vaccine has been extensively studied in Phase III clinical trials and peer-reviewed data confirms the vaccine has been generally well tolerated.”